The purpose of this project is to beta-test a brief waiting room video intervention that promotes early initiation of antiretroviral treatment among treatment-naïve HIV-positive patients, adherence to antiretroviral treatment and retention in care among HIV-positive patients currently on therapy, sexual risk reduction tailored to HIV-positive persons, and patient-initiated discussion of these topics with their health providers. The video is currently being created, and will be ready for beta-testing by June 1, 2016. Results of the beta-testing will be used to refine and improve the video before dissemination to HIV/AIDS treatment facilities nationally. This video project is being funded by the Centers for Disease Control and Prevention, Division of HIV/AIDS Prevention (DHAP).
The overall goal of this study is to beta-test the waiting room video in three HIV/AIDS treatment facilities in different US jurisdictions with high AIDS prevalence. These results will be used to refine the video and to increase its effectiveness among minority persons living with HIV infection. The beta-testing will consist of: 1) unobtrusive observations of waiting room patients for one day at each facility and 2) de-identified, existing patient medical data abstracted from each facility's electronic medical record (EMR) system to investigate outcomes relevant to HIV medication adherence and retention in care.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
4,003
The video's conceptual framework incorporates Social Cognitive Theory, Information-Motivation-Behavioral Skills model, and Social Action Theory, which together address cognitive and behavioral factors related to study outcomes. Storylines embedded prevention messages aimed at increasing treatment initiation (n=9), medication adherence (n=35), retention in care (n=22), partner protection (n=12), and communication with health care providers (n=7).
Antiretroviral therapy (ART) medication adherence (suppression level)
Adherence was measured by whether viral load suppression (\<200 RNA copies/mL) was achieved
Time frame: By 6 months (183 days) after the patient's index (first) visit to the clinic
Antiretroviral therapy (ART) medication adherence (undetectable level)
Adherence was measured by whether viral load suppression (\<50 RNA copies/mL) was achieved
Time frame: By 6 months (183 days) after the patient's index (first) visit to the clinic
Treatment initiation
Treatment initiation was measured by a patient's receipt of an ART prescription
Time frame: on, before, or within 7 days after, their index visit, as documented by OAMC visits in patient EMRs.
Retention in HIV medical care
Measured by an adaptation of the Health Resources and Services Administration's (HRSA) definition in the Annual Ryan White HIV/AIDS Program Services Report
Time frame: 2 or more clinic visits for any reason at least 90 days apart in the past year divided by all active clients who had had at least one such visit in the past year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.